Highlights Newsletter 4
This newsletter presents you the following key sessions:
4. Ravulizumab shows noninferiority versus eculizumab in adult patients with paroxysmal nocturnal haemoglobinuria
naive to complement inhibitors
This newsletter presents you the following key sessions:
4. Ravulizumab shows noninferiority versus eculizumab in adult patients with paroxysmal nocturnal haemoglobinuria
naive to complement inhibitors
Medical writer